GNSC-001
Osteoarthritis of the knee
Pre-clinicalActive
Key Facts
About Genascence
Genascence is a private, pre-revenue biotech focused on revolutionizing the treatment of osteoarthritis through gene therapy. Its lead program, GNSC-001, is a one-time intra-articular injection using an AAV vector to deliver the IL-1 receptor antagonist (IL-1Ra) gene, aiming to provide sustained inhibition of inflammation and cartilage destruction. The company was founded on technology licensed from Mayo Clinic and the University of Florida and is led by a team with deep experience in gene therapy development. Genascence is targeting one of the world's most common causes of chronic pain and disability, representing a massive market opportunity if successful.
View full company profileTherapeutic Areas
Other Osteoarthritis of the knee Drugs
| Drug | Company | Phase |
|---|---|---|
| TG-C (Invossa) | Kolon TissueGene | Phase 3 |
| StroMel™ | Akan Biosciences | Phase 2 |
| XT-150 | Xalud Therapeutics | Phase 2b |